Resistance-busting ICR drug enters clinical trial A drug discovered at The Institute of Cancer Research, London, that could counteract drug resistance in patients with cancers including acute myeloid leukaemia has entered a phase I clinical trial at The Royal Marsden NHS Foundation Trust. The drug, now called EP0042, is a dual inhibitor of cancer-driving proteins [...]
Ellipses updates clinicians at Asco on clinical trial programmes London, UK, 21 November 2022: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, is delighted to announce that it will be presenting clinical updates covering two of its assets at the San Antonio Breast Cancer Symposium [...]
Ellipses Pharma announces FDA approval of IND application for EP0042 for patients with acute myeloid leukaemia IND approval allows for US trial sites and recruitment of eligible US patients to be added to EP0042’s ongoing phase 1/2 trial Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and [...]
Striving to improve treatment options for Acute Myeloid Leukaemia By Professor Tobias Arkenau, Global Head of Drug Development and Chief Medical Officer, Ellipses Pharma If there is one thing a cancer patient wants beyond fast, effective treatment – it is hope. Initial diagnosis is naturally frightening for patients but the realisation that their prescribed treatment [...]
Ellipses announces first patient dosed with EP0031, a next generation selective RET inhibitor Phase 1/2 trial opened in the US with first patient treated in November 2022 London, UK, 14th December 2022: Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, today announces the first dosing of [...]
Ellipses Pharma presents preliminary data from the first in human phase-1/2 trial of EP0042, a dual FLT-3 and Aurora kinase inhibitor, at ASH Study investigated treatment of patients with AML and initial findings suggest that EP0042 had acceptable safety and tolerability, with evidence of disease stabilisation London, UK, 12 December 2022: Ellipses Pharma Limited (“Ellipses”), [...]
Ellipses Pharma presents design of newly initiated phase 1/2a trial of vosilasarm (EP0062) at SABCS Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, will present a “Trial in Progress” poster detailing the design of a Phase 1/2 trial of vosilasarm (EP0062) in advanced breast cancer [...]
The Professor Gordon McVie Cancer Research Leaders Fellowship By Dr Rajan Jethwa, CEO, Ellipses Pharma. If only there were more Professor Gordon McVies. I’m sure that’s what most of us were thinking when we gathered last week to honour the late renowned oncologist and founding chair of the Ellipses Scientific Affairs Group. Eminent figures from [...]
Ellipses Pharma to present clinical updates at leading U.S conferences Ellipses Pharma to present clinical updates at leading U.S. breast and blood cancer conferences London, UK, 21 November 2022: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, is delighted to announce that it will be [...]
Ellipses Pharma to present clinical updates at leading U.S. breast and blood cancer conferences London, UK, 21 November 2022: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, is delighted to announce that it will be presenting clinical updates covering two of its assets at the [...]
